HER2-like And Basal-Like Genotype Breast Cancer Are More Likely To Respond To Chemoth

T

tD33NAt

Active member
Joined
Mar 24, 2008
Messages
12,519
Reaction score
0
Points
36
New data suggest that breast cancer patients with HER2- and basal-molecular subtypes are more likely to respond to neoadjuvant chemotherapy than patients with luminal-type molecular subtype characteristics. The findings were released at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS)...


UvRPMv-1rFk


More...
 
Back
Top